1. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Issue 2 (February 2020) Authors: Doebele, Robert C; Drilon, Alexander; Paz-Ares, Luis; Siena, Salvatore; Shaw, Alice T; Farago, Anna F; Blakely, Collin M; Seto, Takashi; Cho, Byung Chul; Tosi, Diego; Besse, Benjamin; Chawla, Sant P; Bazhenova, Lyudmila; Krauss, John C; Chae, Young Kwang; Barve, Minal; Garrido-Laguna, Ignacio; Li... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Issue 2 (February 2020) Authors: Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G; Shaw, Alice T; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jürgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R; Chiu, Chao-Hua; John, Thomas; Goto, Koichi; Karapetis, Christos S; Arken... Journal: Lancet oncology Issue: Volume 21:Issue 2(2020) Page Start: 261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗